Prospective study to investigate meropenem serum levels in sepsis patients with and without renal replacement therapy

Prospective study to investigate meropenem serum levels in sepsis patients with and without renal replacement therapy - Mero-REPLACE

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00004778

Enrollment

Registered

2013-07-05

Start date

2013-11-04

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

A41.9

Interventions

Group 1: Patients without renal dysfunction: meropenem serum levels on day 3 of meropenem application (0, +1 h, +5 h, +9 h) Group 2: Patients with extended daily dialysis: meropenem serum levels on da

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Sepsis, antimicrobial therapy with meropenem as indicated by the treating physician, age =18 years, in 30 patients: treatment with extended daily dialysis (n=15) or treatment with continuous hemodialysis (n=15)

Exclusion criteria

Exclusion criteria: age <18 years, pregnant or lactating women, meropenem in cerebral infections, participation in another interventional trial, other renal replacement therapy as daily extended dialysis or continuous hemodialysis, dialysis in the last 12 hours before study inclusion, acute kidney failure (creatinine clearance <80 ml/min) without indication for renal replacement therapy, no commitment for full organ support (i.e. DNR order), not expected to survive this hospital stay because of preexisting diseases, staff and their relatives

Design outcomes

Primary

Measure	Time frame
Duration of the area under the serum concentration-time curve (AUC) above 4fold minimal inhibitory concentration (MIC) (time points of measurement of meropenem serum levels see arm 1-3)	—

Secondary

Measure	Time frame
Course of meropenem serum levels, Clinical course of infection, procalcitonin, c-reactive protein, leukocytes at day 7, Meropenem concentrations in urine and ultrafiltrate, ICU and hospital length of stay, ICU (intensive care unit) and hospital mortality	—

Countries

Germany

Contacts

Public ContactIsabella Westermann

Universitätsklinikum Jena - Klinik für Anästhesiologie und Intensivtherapie

isabella.westermann@med.uni-jena.de+49-3641-9323 180

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026